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The parent of origin-dependent expression of the IGF2 and H19 genes is controlled by the imprinting centre 1
(IC1) consisting in a methylation-sensitive chromatin insulator. Deletions removing part of IC1 have been
found in patients affected by the overgrowth- and tumour-associated Beckwith–Wiedemann syndrome
(BWS). These mutations result in the hypermethylation of the remaining IC1 region, loss of IGF2/H19 imprint-
ing and fully penetrant BWS phenotype when maternally transmitted. We now report that 12 additional cases
with IC1 hypermethylation have a similar clinical phenotype but showed neither a detectable deletion nor
other mutation in the local vicinity. Likewise, no IC1 deletion was detected in 40 sporadic non-syndromic
Wilms’ tumours. A detailed analysis of the BWS patients showed that the hypermethylation variably affected
the IC1 region and was generally mosaic. We observed that all these cases were sporadic and in at least two
families affected and unaffected members shared the same maternal IC1 allele but not the abnormal maternal
chromosome epigenotype. Furthermore, the chromosome with the imprinting defect derived from either the
maternal grandfather or maternal grandmother. Overall, these results indicate that methylation-imprinting
defects at the IGF2–H19 locus can result from inherited mutations of the IC and have high recurrence risk
or arise independently from the sequence context and generally not transmitted to the progeny. Despite
these differences, the epigenetic abnormalities are usually present in the patients in the mosaic form and
probably acquired by post-zygotic de novo methylation. Distinguishing between these two groups of
cases is important for genetic counselling.
INTRODUCTION
There is increasing evidence that aberrant chromatin states
leading to aberrant gene expression patterns (epimutations)
have important roles in human disease (1,2). However, many
characteristics of these lesions are still undefined. For instance,
although it is generally accepted that epigenetic marks are
cleared between generations, there are a number of cases in
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which this seems not to be the case. Indeed, the causes, herit-
ability and relationship with phenotype of some epimutations
have recently been the matter of debate (3–7). The human dis-
orders caused by defects of genomic imprinting provide a
paradigm for studying these issues.
Genomic imprinting is a mechanism causing the expression
of a minority of genes to be monoallelic and dependent on
their gametic origin (8,9). Imprinted genes are often organized
in clusters and their gamete of origin-specific expression is
controlled by cis-acting elements termed imprinting centres
(ICs). These sequences are marked by different epigenetic
modifications (of which DNA methylation is an essential
one) on their maternal and paternal alleles. These molecular
imprints are established during gametogenesis, maintained in
the zygote and throughout embryo development and replaced
by the new ones in the new generation of germ cells. In the
somatic cells, the ICs direct by different mechanisms the
parent of origin-specific expression of the imprinted genes.
A 1 Mb cluster of imprinted genes lies on chromosome
11p15.5. This cluster is functionally divided into two
domains that are autonomously controlled by distinct ICs
[IC1 and IC2 (10,11)]. Defective expression of the 11p15.5
imprinted genes results in the Beckwith–Wiedemann syn-
drome (BWS, MIM 130650).
BWS is a developmental disorder characterized by variable
clinical features, including overgrowth, macroglossia, abdomi-
nal wall defects and increased incidence of embryonal tumours
(12). The majority of the BWS cases are sporadic. The rare
familial cases show predominantly autosomal dominant
inheritance and preferential expression following maternal
transmission. Heterogeneous molecular defects are found in
BWS (12). Only 5% of the cases (40% of the familial ones)
have typical single-gene defects, consisting in loss-of-function
mutations of CDKN1C. Approximately 20% of the cases have
uniparental paternal disomy (UPD) of 11p15.5 loci, indicating
that BWS is caused by excess of imprinted genes expressed
from the paternal chromosome and/or defect of imprinted
genes expressed from the maternal chromosome. The majority
of the other cases show DNA methylation defects at either IC1
or IC2. These are accompanied by deregulation (either bialle-
lic activation or biallelic silencing) of Domain 1 or Domain 2
imprinted genes. Microdeletions of the ICs that account for the
regulatory defects have been found in some of these patients
(13–17). Although many phenotypic characteristics are in
common between different molecular subtypes of BWS, sig-
nificant differences have been found for some of the clinical
features of BWS, such as tumour risk, severity of anterior
abdominal wall defect, birth weight, hemihypertrophy and
ear signs (18–20).
Two genes, insulin-like growth factor 2 (IGF2) and H19,
are located in Domain 1 of the 11p15.5 imprinted gene
cluster. IGF2 is a paternally expressed fetal growth factor.
H19 is a maternally expressed non-coding RNA with possible
tumour-suppressor functions (21). The reciprocal imprinting
of IGF2 and H19 is controlled by IC1 in the majority of
tissues. The function of this control element has been exten-
sively studied in the mouse. IC1 [also known as H19 differen-
tially methylated region (DMR)] is a methylation-sensitive
chromatin insulator that is located between Igf2 and H19
(22,23). The maternal and paternal IC1 alleles acquire
differential methylation during gametogenesis. In the
somatic cells, the non-methylated maternal allele interacts
with the zinc-finger protein CTCF. This binding is required
for preventing de novo methylation of the region, insulating
the maternal Igf2 promoter from downstream enhancers and
activating the maternal H19 gene. On the paternal chromo-
some, instead, DNA methylation prevents CTCF binding at
IC1 and allows Igf2 activation by the enhancers while the
paternal H19 promoter becomes hypermethylated and
silenced. Recent evidence indicates that CTCF binding at
IC1 mediates higher-order chromatin conformations in a
parent of origin-specific manner (24–26). This may partition
the paternal and maternal Igf2 alleles into active and inactive
chromatin domains, respectively. Five to ten percent of the
patients with BWS have methylation of IC1 on both parental
chromosomes. This results in biallelic activation of IGF2
and biallelic silencing of H19 in all tissues (27). Patients
with this type of defect have higher risk of developing
cancer and particularly Wilms’ tumour (WT) than patients
belonging to other molecular subgroups (18). Similar to
BWS, patients with non-syndromic WT also have IC1 hyper-
methylation with IGF2 activation and H19 silencing, but this
is restricted to cancer tissues in these cases (28).
Deletions of the IC1 region of the order of 1.4–1.8 kb have
been found in BWS patients with IC1 hypermethylation
(13,16,17). These cases are part of dominant inheritance pedi-
grees with maternal transmission. The deletions remove one to
two target sequences for CTCF (CTSs) resulting in hyper-
methylation of the residual CTSs and co-segregate with the
BWS phenotype. We found no deletion in other phenotypi-
cally similar BWS cases. In this paper, we investigate the
cause of defective imprinting of IGF2–H19 in 12 individuals
with IC1 hypermethylation and no associated deletion. The
results obtained suggest that these cases result from sporadic
epimutations arising independently from the sequence
context, probably at post-zygotic stages and have low recur-
rence risk. Similarly, sporadic methylation defects without
accompanying IC1 deletion were found in a large series of
non-syndromic WTs.
RESULTS
Search for IC1 deletions
We identified 21 individuals with the clinical features of BWS
and hypermethylation of the IC1 and H19 promoter regions as
determined by Southern blotting (data not shown). Nine of
these patients carried IC1 deletions and were part of five domi-
nant pedigrees with maternal transmission (13,17). No dele-
tion in the IC1 region was identified in the remaining 12
individuals by Southern blotting and long-range PCR (data
not shown). In a previous study, the promoter and transcribed
sequences of H19 were sequenced in the DNAs of the patients
BWS-16 and BWS-19 and no deletion or other mutation apart
normal polymorphisms was found (29). We have now ana-
lysed the H19 promoter region by Southern blotting and
sequenced the parts of the H19 transcribed region correspond-
ing to known SNPs in all other patients. The normal pattern of
bands detected by Southern blotting in all cases and the finding
that most patients were heterozygous for at least one H19
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intragenic polymorphic sequence variant excludes the pre-
sence of large H19 gene and promoter deletions in most
cases (data not shown). Furthermore, neither mutation of the
CDKN1C gene apart from normal polymorphisms (30) nor
methylation defects at IC2 or 11p15.5 UPD were found in
these patients (data not shown). All these cases were sporadic.
The clinical features of these individuals and those carrying
IC1 deletions are reported in Table 1. Overall, the phenotypes
of these two groups of patients are very similar, both including
the characteristics more often found in the BWS patients with
defect of the IGF2-H19 imprinting domain, such as pro-
nounced macrosomia, mild or absent defects of the abdominal
wall and elevated incidence of WT (18).
Since IC1 deletions were present in 2/6 of the WTs devel-
oped in our BWS patients (Table 2), we looked for the pre-
sence of such mutations in sporadic cases of WT without
other features of BWS. Consistent with the high frequency
of 11p15.5 imprinting defects reported in these neoplasms,
10/40 of these tumours had IC1 hypermethylation by methyl-
ation restriction-PCR assay (MR-PCR or COBRA; Table 2).
However, no IC1 deletion was detected in any of the 40
tumour cases by long-range PCR (Table 2).
Sequence analysis of IC1
The human IC1 region has a repetitive structure and contains
seven target sites for CTCF (CTS) in 4 kb, with the first six
CTSs arranged in two clusters of three sites each (Fig. 1A).
In order to identify the cause of the epigenetic defect in the
patients with IC1 hypermethylation and no deletion detected
by Southern blotting, we searched for very small deletions
or point mutations by sequencing the entire 4 kb region.
However, no deletion was found in any of the 12 patients by
this procedure. Some single-nucleotide variations with
respect to the reference sequence (AF125183) were detected,
but most of them corresponded to polymorphisms also found
in the normal population. Indeed, common SNPs are present
in three of the seven target sequences for CTCF
(rs10840167, rs11042170, rs10732516). Few novel base sub-
stitutions were identified but none of them was de novo or
present in more than one patient (Table 3). Since most of
the patients were heterozygous for at least one SNP, the pre-
sence of larger deletions of the IC1 region was also excluded.
It is therefore unlikely that the IC1 hypermethylation found in
these patients is caused by a mutation in this region.
DNA methylation and imprinting analysis
The analysis of methylation by Southern blotting does not
provide information on the methylation status of the CTSs
of the IC1 region. We have previously used MR-PCR or
COBRA to demonstrate that the maternal transmission of
IC1 deletions is associated with hypermethylation at all the
remaining CTSs and the H19 promoter while 50% methylation
is present in control individuals (17). We now used this pro-
cedure to analyse the 12 patients with hypermethylation at
IC1 and no accompanying deletion (Fig. 1A). The results
obtained showed differences in the extent of methylation of
the individual CTSs and H19 promoter in these patients.
Methylation was analysed in the peripheral blood leukocytes
and ranged from 50 to 99% at different sites and in different
patients. In addition, the degree of methylation was more
homogeneous among the CTSs belonging to the same cluster
and the CTSs 4–7 and H19 promoter were generally more
methylated than the CTSs 1–3. Three individuals (BWS-12,
BWS-19 and BWS-21) showed this characteristic in a more
pronounced manner, having 50–60% methylation at the first
three CTSs and 76–90% methylation at the further four
CTSs and H19 promoter. The bisulfite-sequencing analysis
confirmed the contrasting methylation between the 50 and 30
part of IC1 in these patients (Fig. 1B). DNA derived from
the skin fibroblasts was available from patient BWS-12 and
the MR-PCR demonstrated 80–90% methylation at the
CTSs 4–6 and 50–57% methylation at the CTSs 1–3 also
in this tissue (data not shown). We also analysed IC1 and
H19 methylation at the CTSs and H19 promoter in the
parents of the patients without IC1 deletion and in nine of
their unaffected sibs and found methylation levels comparable
to control individuals (data not shown). We then asked
whether the methylation abnormality was specific for the
IC1 or was extended to other imprinted loci. In addition to
the 11p15.5 IC2, which had already been found normally
methylated (see above), we analysed the DMRs of GTL2/
DLK1, PEG3, ZAC and IGF2R by using MR-PCR
(COBRA). We found 50% methylation at all these loci in
all our patients as well as in 50 control individuals (data not
shown).
We have previously reported that the BWS patients with
hypermethylation and silencing of H19 express IGF2 from
both the maternal and paternal alleles (27,31). Two of these
cases were further analysed in this manuscript (BWS-16 and
BWS-19) and demonstrated to have the entire IC1 region or
only the CTSs 4–7 hypermethylated, respectively (Fig. 1A).
We now investigated the allele-specific expression of IGF2
and the overall expression of H19 in the RNA derived from
the skin fibroblasts of the patient BWS-12. The results demon-
strated expression from both parental IGF2 alleles, whereas
expression from only the paternal allele was evident in the
control, indicating loss of IGF2 imprinting also in this case
(Fig. 1C). In addition, H19 RNA levels were 9-fold lower
than in an age-matched control. No phenotypic difference
was evident between the two groups of patients differing in
the extension of the methylation defect at IC1. Overall,
these results indicate that, in the BWS patients without IC1
deletion, the abnormal methylation extends over the entire
IC1 region or affects mostly its 30 half. All these cases, regard-
less of the extension of the methylation defect in the IC1, also
have hypermethylation (and probably silencing) of H19 and in
several of them IGF2 has been demonstrated to be activated
on both parental alleles. Furthermore, the methylation defect
is specific for the 11p15.5 IC1 locus, is generally incomplete
suggesting epigenetic mosaicism, and is not present in the
unaffected relatives.
Segregation of 11p15.5 haplotypes
Since BWS results from an imprinting defect on the maternal
chromosome, we analysed the segregation of the maternal
IC1 allele of the index patient in the families without IC1
microdeletion after construction of 11p15.5 haplotypes by
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microsatellite analysis (Fig. 2A). In one family (BWS-20), the
affected and an unaffected sib inherited the same 11p15.5 hap-
lotype from their mother. In three additional families
(BWS-11, BWS-17 and BWS-21), different 11p15.5 haplo-
types were transmitted to the patients and their healthy sib-
lings from their mothers. However, in family BWS-11, the
propositus and her healthy mother shared the same 11p15.5
haplotype on the maternal chromosome. So, in at least two
families, affected and non-affected individuals had the same
maternal IC1 allele.
The grandparental origin of the chromosomes carrying the
imprinting defect was determined by microsatellite analysis
(Fig. 2A) or (if grandparents were not available) DNA
methylation/SNP test (Fig. 2B). In this procedure, the grand-
paternal and grandmaternal IC1 alleles were distinguished in
the DNA of the mothers because of their differential methyl-
ation (which was always all-or-none on the two parental
alleles) determined by bisulfite sequencing. In case of het-
erozygosity, SNPs were used to determine which maternal
allele was transmitted to the probands. Overall, the results
showed that in five informative cases the chromosome carry-
ing the imprinting alteration derived from the maternal
grandfather, whereas in one case derived from the maternal
grandmother (Table 4).
Mutation analysis of CTCF
Since CTCF binding is required for preventing de novo
methylation at IC1 (32–35), we looked for mutations at the
CTCF locus in the BWS patients with IC1 hypermethylation
and no accompanying defect in cis. We sequenced all exons
and flanking intronic regions in six of such patients. Only a
single-nucleotide variation with respect to the reference
sequence (NT_010498, nucl. 21210663–21287287) was
found in the 50-UTR (Ex1 C/G19) of one individual
(BWS-10) and an SNP also present in the normal population
was found in the 30-UTR (rs6499137) of another individual
(BWS-12). No change in the coding sequence was present in
any of these patients. Hemizygosity at the CTCF locus was
also excluded in all cases by analysing a microsatellite
present in intron 7 (rs3223529). Therefore, these results indi-
cate that CTCF gene mutations are not a common cause of
IC1 hypermethylation in BWS.
DISCUSSION
Gain of methylation defects at IC1 are found in only 5–10%
of the BWS cases (12,18). However, the high incidence of
WT associated with these molecular abnormalities makes
them particularly important to study. Some of the patients
with this type of abnormal methylation have been demon-
strated to have germline deletions in the IC1 region and
high recurrence risk (13,17). Other BWS patients with
similar epigenetic defect at IC1 had no associated deletion.
It was unclear whether these patients had any other mutation
in cis, what was the nature of their molecular defect and
what was their recurrence risk. By analysing 12 patients
Table 1. Clinical features of the BWS patients with IC1 hypermethylation
Clinical features IC1 hypermethylation without microdeletion IC1 hypermethylation with microdeletion
Macrosomia (weight perc. .90) 9/11 7/8
Polydramnios 2/11 2/8
Macroglossia 9/11 7/8
Rectum diastasis 6/11 5/8
Umbilical hernia 6/11 3/8
Exomphalos 0/11 0/8
Inguinal hernia 1/11 0/8
Hemihypertrophy 3/11 4/8
Facial asymmetry 2/11 2/8
Hepato-/spleno-megaly 7/11 4/8
Neonatal hypoglycaemia 6/11 2/8
Ear pits/creases 4/11 2/8
Facial dysmorphology 4/11 3/8
Naevus flammeous 2/11 3/8
Renal abnormalities 6/11 4/8
WTa 2/11 (2/9) 2/8 (2/6)
Ureteral abnormalities 1/11 2/8
VSD/ASD/PDA shunt 1/11 0/8
Convulsions 1/11 0/8
Mental retardation 0/11 1/8
aIncidence at .6 years is shown in parenthesis.
Table 2. Molecular defects at 11p15.5 in syndromic and non-syndromic WTs
Molecular defect Non BWS-Wilms
(n ¼ 40)
BWS Wilms
(n ¼ 6)
IC1 hypermethylation with
microdeletion
0 2
IC1 hypermethylation without
microdeletion
10 2
Loss of maternal allele (UPD or
LOH)
18 2
No defect 12 0
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Figure 1. Methylation of the CTSs and H19 promoter and IGF2 and H19 expression in the BWS patients with IC1 hypermethylation and no associated dele-
tion.(A) Summary of the results obtained on 12 BWS patients and 40 control individuals. DNA methylation at CpGs included in the CTSs and H19 promoter was
assayed by MR-PCR (COBRA) in leukocyte DNA. The average methylation levels detected in control individuals (50+5%) are shown for comparison. The
extent of methylation at each CpG site is indicated with pie charts filled in black. Each sample was run in duplicate. SD was 5%. A diagram showing
the structure of the human IC1 region is present in the upper part of the figure. A- and B-type repeats are indicated by boxes of different colours, whereas
the CTSs are indicated by triangles. (B) DNA methylation profiles of CTCF site 1 and CTCF site 6 and flanking regions in patients BWS-19 and BWS-12
and a control individual, as determined by bisulfite-genomic sequencing. Each line corresponds to a single template DNA molecule cloned; each circle corre-
sponds to a CpG dinucleotide. Filled circles designate the methylated cytosines; open circles, unmethylated cytosines. The CpGs included in the CTCF sites are
framed. When indicated, the parental alleles were discriminated by SNPs. (C) Analysis of IGF2 and H19 expression in patient BWS-12. RNAs extracted from
cultured skin fibroblasts of the patient and a control individual were analysed by reverse transcriptase–PCR. In the upper panel, the parental alleles of IGF2 were
discriminated by typing for a direct repeat polymorphism (Can repeat) present in the 3
0-untraslated region of the IGF2 gene. Three different alleles were
observed. Both the maternal and paternal IGF2 alleles (a and b) were expressed in the fibroblasts of the patient, but only the paternal allele (b) was expressed
in the control. To exclude contamination from DNA, the RNAs were amplified with (RTþ) and without (RT2) previous treatment with reverse transcriptase. In
the lower panel, the overall H19 RNA was determined by quantitative real-time RT–PCR using primers specific for the H19 transcript and the GAPD mRNA.
Note that in the BWS patients without IC1 deletion the hypermethylation is generally mosaic and affects predominantly the CTSs that are closer to the H19
promoter. Regardless of the extension of the IC1 methylation defect, all these cases also have hypermethylation of H19 and several of them have been demon-
strated to express IGF2 from both parental alleles and have H19 silenced.
Human Molecular Genetics, 2008, Vol. 17, No. 10 1431
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/17/10/1427/594264 by U
niversità degli Studi di M
ilano - Scienze politiche user on 07 April 2020
with IC1 hypermethylation and no deletion, we found no
mutation in the critical IC1 elements and demonstrated that,
in at least two cases, the maternal IC1 allele of the index
patient segregated in one of his healthy relatives. A detailed
methylation analysis showed that the hypermethylation was
extended over the entire or only the 30 half of the IC1
region, did not affect other imprinted loci, generally occurred
in the mosaic form and was never present in the unaffected
relatives. We also observed that the chromosome carrying
the imprinting abnormality derived from either the maternal
grandfather or maternal grandmother. These results indicate
that, in the absence of deletions, IC1 hypermethylation gener-
ally occurs as sporadic epimutation and is associated with low
recurrence risk. Consistent with this conclusion, no deletion
was detected in a large series of non-syndromic sporadic WTs.
In the mouse, the CTSs have been shown to be required for
the post-zygotic maintenance of the methylation-free status of
the maternal IC1 allele (32–35). Consistent with these obser-
vations, deletions removing one to two CTSs of the human
IC1 result in the hypermethylation of its maternal allele
(13,17). However, we found no mutation in any of the seven
CTSs of another 12 BWS patients with IC1 hypermethylation.
In addition, the segregation of the chromosome with the
imprinting defect in the healthy relatives excludes inherited
mutations in the entire chromosome 11p15.5 region of two
individuals. Therefore, although we cannot rule out the pre-
sence of de novo mutations at sites distant from IC1, our
results strongly support the hypothesis that in a subset of
BWS patients IC1 epimutations occurr independently of the
sequence context.
We previously observed that all IC1 CTSs are completely
and exclusively methylated on the paternal chromosome in
normal leukocyte DNA, whereas incomplete hypermethyla-
tion of the maternal allele is present in the BWS patients
with 1.4–1.8 kb IC1deletions (17). We now found incomplete
methylation at IC1 also in the majority of patients without
deletions suggesting that this imprinting defect is generally
present in the mosaic form. Mosaicism can in part explain
the high variability of the clinical phenotype that is character-
istic of this disorder. In addition, diagnostic problems may be
encountered with individuals who may not have abnormal
methylation in their leukocyte DNA. To avoid these problems,
it may be useful in the future to analyse DNAs derived from
more than one tissue (e.g. blood leukocytes and buccal
mucosa).
Imprinting defects at ICs can derive from failure of erasure,
establishment or maintenance of the parental marks (8). One
way to approach this problem is to investigate the grandparen-
tal origin of the chromosome with the imprinting defect (36).
We found that in the BWS patients the chromosome with
abnormal IC1 methylation derived from either the maternal
grandfather or the maternal grandmother. Since the majority
of these cases also showed mosaic hypermethylation, it is
likely that the methylation defect was acquired after erasure
of the parental epigenetic marks and probably at a post-zygotic
stage as result of defective protection from de novo methyl-
ation of the maternal IC1 allele. A similar mechanism is
also likely to be involved in the cases with IC1 deletion
(17). However, an incomplete imprint erasure resulting in an
unstable methylation is also possible, at least in some cases.
The ultimate effect of IC1 methylation on the maternal
chromosome is H19 silencing (by methylation spreading into
the promoter region) and IGF2 activation [by inactivation of
the insulator activity (8)]. We found that in some of the
BWS patients hypermethylation is more evident on the four
CTSs that are located closer to the H19 promoter. This may
indicate that methylation of the CTSs 4–7 is sufficient to
cause silencing of H19 and/or activation of IGF2. Indeed,
gain of methylation at the H19 promoter was observed in all
the patients regardless of the extension of IC1 hypermethyla-
tion and biallelic activation of IGF2 could be demonstrated
in two of the patients with limited IC1 methylation.
Table 5. PCR primers used for the sequence analysis
H19 Forward primer Reverse primer
Ex1 50-tggcggggagaagcagacac-30 50-gcgtcaccaagtccactgtg– 30
Ex 4/5 50-ttcctgccacacttggggtg-30 50-tgatgtggtggctggtggtc-30
Ex 5 50-ccaccagccaccacatcatc-30 50-gaaggctgctccgtgatgtc-30
CDKN1C Forward primer Reverse primer
Promoter 50-gcgccctttaactcccgccc-30 50-gctagctcgctcgctcaggc-30
50-UTR 50-gggctgggcgttccacaggc-30 50-gatgtgctgcggagggacgc-30
30-UTR 50-ctcggctgggaccgttcatg-30 50-agctagtgcgtggcagagcg-30
CTCF Forward primer Reverse primer
Ex1 50-cgtcccttcccttatcagcac-30 50-cccatcgtgacacctagaggc-30
Ex2 50-atggctcggttagtgacatg-30 50-gccaacaaatcctccaactc-30
Ex3 50-gcctaattcattcaccaaag-30 50-cccctgaagttcttctactg-30
Ex3 50-atatggaggaacagcccataaac-30 50-caacttgcatatgcactgtgttg-30
Ex4 50-aacactttgaaactctgcagcaag-30 50-cgctggagtcagcttgaatg-30
Ex5 50-catagcagttctgtgccacac-30 50-tcatcttaagtccgtttgggtag-30
Ex6 50-actgtgctcttgttacagtctgtg-30 50-aacaatggggacacacagtg-30
Ex7 50-gtgtagcatatctgccacctg-30 50-tgttatgagagtcagaaggtgaag-30
Ex8 50-gaatcgagaaatgtattagtaacttg-30 50-gtgacattcctcataatccacag-30
Ex9 50-aatacctgttggccacatgc-30 50-accatgctctgcagaggaag-30
Ex10 50-gagcctccccttagagaacc-30 50-gcctctatatcccagcatatcc-30
Ex11 50-ttcatcttccaccacccttctc-30 50-gacttcctcagatgttcctcagt-30
Ex12 50-cattgctgacatcccgttc-30 50-gaccataccagaaactttgcc-30
Ex12 50-gcttggagtcagctgcaca-30 50-cagcctggaaccatgtatgc-30
Table 3. Sequence variations of the IC1 region
Patient Variation Position (accession no. AF125183)
BWS-10 A/G 7679
BWS-12 T/Ca 5198
BWS-14 C/T 4936
BWS-18 T/C 6653
BWS-19 G/A 4613
G/A 5906
aT5198.C was present in homozygosity in this individual.
Table 4. Grandparental origin of the chromosome carrying the imprinting
defect
Origin IC1 microdeletion No IC1 microdeletion
Maternal grandmother 1 1
Maternal grandfather 8a 5
aIn one patient, the deletion is de novo or due to germline mosaicism.
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Cooperative interaction between proteins bound to adjacent
CTSs (33) may explain the more homogeneous methylation
inside each cluster of CTSs.
Since we did not find a mutation in cis, it is possible that a
regulatory trans-acting factor is defective in the BWS cases
with IC1 hypermethylation and no deletion. Knocking-down
of CTCF in mouse oocytes and in cultured cells results in
gain of methylation of IC1 (7,37). We ruled out the presence
of a mutation of the CTCF gene in our patients. It cannot be
excluded, however, that a mutation is present in other modifier
genes. Considering the sporadic nature of these cases, the
possibility that IC1 hypermethylation occurs as consequence
of stochastic events or environmental influence should also
be envisaged (38).
The 11p15.5 imprinted gene cluster is frequently affected in
WTs (28). Either maternal deletion/paternal duplication
(LOH) or IC1 hypermethylation coupled to H19 silencing
and IGF2 activation (LOI) can be found in a high proportion
of tumours (see also Table 2). In addition, the individuals
who have soma-wide IC1 hypermethylation or 11p15.5
paternal UPD represent the molecular subgroup of BWS
patients showing the highest risk of developing WT (18–
20). Consistent with these observations, we found that 2/6
BWS patients with IC1 deletion had developed this neoplasm
by 6 years of age. However, no IC1 deletion was found in 40
sporadic non-syndromic WTs enrolled by Pediatric Oncology
Units affiliated to Associazione Italiana Ematologia Oncologia
Pediatrica (AIEOP). A previous American study demonstrated
the absence of point mutations in the IC1 sequence of a series
of sporadic WTs (39). Overall, these data suggest that IC1
imprinting defects are generally not caused by a mutation in
cis in non-syndromic WT as well as sporadic BWS.
Although the common hallmark and probably the ultimate
cause of the imprinting defects at the IGF2/H19 locus is rep-
resented by hypermethylation of IC1, our studies demonstrate
that this epigenetic abnormality can result from more than one
mechanism in BWS and WT. In a first group of patients, we
found that the epimutation is a direct consequence of a
mutation in cis, consisting of a deletion of one to two CTSs.
In these cases, the methylation defect and disease phenotype
are reproduced whenever the mutation is transmitted through
the maternal germline. In another group of patients, who
carry no IC1 deletion, the epimutation is independent of the
local DNA sequence and generally not transmitted to the
progeny. Sporadic BWS and non-syndromic WTs belong to
the second group of cases. Despite these differences, the IC1
epimutation is generally present in the patients in the mosaic
form and probably acquired by postzygotic de novo methyl-
ation, providing an example of how intricate the relationship
between genotype and epigenotype can be.
MATERIALS AND METHODS
Patients
BWS was diagnosed in all patients according to the criteria
described in the literature (http://www.geneclinics.org). The
clinical features of the BWS patients included in this study
are summarized in Table 1. The study included 40 WT patients
enrolled in the AIEOP 2003 WT trial. In 37 of these cases,
there was no evidence of associated congenital abnormalities.
The three other cases were associated with WAGR, Turner
and Down syndrome phenotypes, respectively.
All the genetic analyses were performed after the informed
consent was obtained from the parents of the patients. The
experimental plan was approved by the ethical committees
of the Second University of Naples and Istituto Nazionale
Tumori, INT, Milan.
Southern blot, PCR, DNA sequencing and microsatellite
analyses
Southern blot hybridization was performed on DNA purified
from blood leukocytes as described (13,31). PCR amplifica-
tion of the H19 DMR was obtained from leukocyte DNA by
using the primers 50-AGAGATGGGATTTCGTCAGGTTG
G-30 and 50- CATTTCCGTCTCCACAGCCACAAC-30 and
the Taq BIO-X-ACT Long (BIOLINE) as described (13).
The fragments generated were gel-purified and cloned into
pCR II (Invitrogen). The primers used for sequencing the
H19 and CTCF gene and the promoter, 50-UTR and 30-UTR
of CDKN1C are reported in Table 5. The primers used for
sequencing CDKN1C exons 3–4 were previously described
(40). DNA sequencing was obtained from PRIMM (Italy).
UPD and LOH at 11p15.5 loci were determined by microsatel-
lite analysis, as described (18).
DNA methylation analyses
The DNA methylation of IC1 (H19 DMR) and H19 promoter
was analysed by HpaII digestion and Southern blot hybridiz-
ation, sodium bisulfite sequencing and bisulfite treatment
coupled with restriction enzyme digestion (MR-PCR), as
described (13). The methylation of IC2 (KvDMR1) was
Table 6. MR-PCR conditions for the methylation analysis of the DMRs at ZAC, IGF2R, PEG3 and GTL2/DLK1 loci
Locus PCR primers Annealing temperature MgCl2 PCR product size Enzyme
ZAC F: 50-gtgtgggtgtygtttagttttttt-30 558C 2 mM 224 bp TaqI
R: 50-aactaaataacaaataacaaatacc-30
IGF2R F: 50-tatgttggggataggttttgggag-30 558C 1.5 mM 330 bp BstUI
R: 50-taaaataacccctctatatcaaaaacccc-30
PEG3 F: 50-tattttagtgggtggggtttgagtag-30 578C 1.5 mM 322 bp BstUI
R: 50-ccctaaacctcctaaactaaatctaaaaac-30
GTL2/DLK1 F: 50-ttaggttggaattgttaagagtttgtggatt-30 608C 1.5 mM 384 bp TaqI
R: 50-ataaactacactactaaaaactacatttaaa-30
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analysed by NotI digestion and Southern blotting hybridiz-
ation, as described (18). The DNA methylation of the DMRs
of ZAC, IGF2R, PEG3 and GTL2/DLK1 were analysed by
MR-PCR. The PCR conditions and the enzymes used for
each DMR are described in Table 6.
Gene expression analysis
The allele-specific expression of IGF2 and the overall
expression of H19 were analysed as previously described (13).
ELECTRONIC-DATABASE INFORMATION
URLs for data in this article are as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.
ncbi.nlm.nih.gov/Omim [for BWS (MIM 130650)]. http://
www.mgu.har.mrc.ac.uk/research/imprinting/;http://igc.otago.
ac.nz/home.html; http://www.geneclinics.org
ACKNOWLEDGEMENTS
We thank the contribution of the AIEOP Wilms Tumor Scien-
tific Committee, all the patients and their families for their
participation in this study.
Conflict of Interest statement. None declared.
FUNDING
This work was supported by grants from MIUR PRIN 2005 (to
A.R. and M.V.C), Istituto Superiore di Sanita` (to A.R.), Associa-
zione Italiana Ricerca sul Cancro (to A.R. and D.P.),
Telethon-Italia Grant No. GGP04072 (to A.R.), Associazione
Bianca Garavaglia, Busto Arsizio, Varese, Italy (to D.P.) and
WellChild (to E.R.M.). F.C. was recipient of a fellowship
from Societa` Italiana di Cancerologia and Fondazione
Pezcoller. A.S. was supported by a fellowship from the Regional
Competence Center on Genomics (GEAR) of Regione
Campania.
REFERENCES
1. Horsthemke, B. (2006) Epimutations in human disease. Curr. Top.
Microbiol. Immunol., 310, 45–59.
2. Feinberg, A.P. (2007) Phenotypic plasticity and the epigenetics of human
disease. Nature, 447, 433–440.
3. Suter, C.M. and Martin, D.I. (2007) Inherited epimutation or a haplotypic
basis for the propensity to silence? Nat. Genet, 39, 573.
4. Suter, C.M. and Martin, D.I. (2007) Reply to ‘Heritable germline
epimutation is not the same as transgenerational epigenetic inheritance’.
Nat. Genet, 39, 575–576.
5. Horsthemke, B. (2007) Heritable germline epimutations in humans. Nat.
Genet., 39, 573–574.
6. Chong, S., Youngson, N.A. and Whitelaw, E. (2007) Heritable germline
epimutation is not the same as transgenerational epigenetic inheritance.
Nat. Genet., 39, 574–575.
7. Leung, S.Y., Chan, T.L. and Yuen, S.T. (2007) Reply to ‘Heritable
germline epimutation is not the same as transgenerational epigenetic
inheritance’. Nat. Genet., 39, 576.
8. Reik, W. and Walter, J. (2001) Genomic imprinting: parental influence on
the genome. Nat. Rev. Genet., 2, 21–32.
9. Edwards, C.A. and Ferguson-Smith, A.C. (2007) Mechanisms regulating
imprinted genes in clusters. Curr. Opin. Cell Biol., 19, 281–289.
10. Ainscough, J.F.X., Koide, T., Tada, M., Barton, S. and Surani, M.A.
(1997) Imprinting of Igf2 and H19 from a 130 kb YAC transgene.
Development, 124, 3621–3632.
11. Cerrato, F., Sparago, A., Di Matteo, I., Zou, X., Dean, W., Sasaki, H.,
Smith, P., Genesio, R., Bruggemann, M., Reik, W. and Riccio, A. (2005)
The two-domain hypothesis in Beckwith–Wiedemann syndrome:
autonomous imprinting of the telomeric domain of the distal chromosome
7 cluster. Hum. Mol. Genet., 14, 503–511.
12. Weksberg, R., Shuman, C. and Smith, A.C. (2005) Beckwith–Wiedemann
syndrome. Am. J. Med. Genet. C Semin. Med. Genet., 137, 12–23.
13. Sparago, A., Cerrato, F., Vernucci, M., Ferrero, G.B., Cirillo Silengo, M.
and Riccio, A. (2004) Microdeletions in the human H19 DMR result in
loss of IG F2 imprinting and Beckwith–Wiedemann. Nat. Genet., 36,
958–960.
Figure 2. Segregation of chromosome 11p15.5 genotypes in BWS families with
IC1 imprinting defect and no associated deletion. (A) Construction of haplotypes
by microsatellite analysis. The haplotype associated with the imprinting defect in
the patient is framed. The chromosome location of the IC1 region is between TH
and D11S1318. (B) Determination of the grandparental origin of the chromo-
some with the imprinting defect by combined DNA methylation/SNP test. The
methylation of the IC1 region was analysed by bisulfite sequencing in the
mothers of patients BWS-20, BWS-12 and BWS-14. Alleles were discriminated
by SNPs and parental origin was assessed by assuming that the paternal IC1
allele was methylated and the maternal IC1 allele was not in normal individuals.
DNA sequencing allowed to determine which maternal allele was transmitted to
the probands. The SNPs and their positions in the AF125183 sequence are indi-
cated. Note that affected and unaffected individuals share the same IC1 allele on
the maternally inherited chromosome in some families and the chromosome with
the imprinting defect in the probands derive from either the maternal grandfather
or maternal grandmother.
1434 Human Molecular Genetics, 2008, Vol. 17, No. 10
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/17/10/1427/594264 by U
niversità degli Studi di M
ilano - Scienze politiche user on 07 April 2020
14. Niemitz, E.L., DeBaun, M.R., Fallon, J., Murakami, K., Kugoh, H.,
Oshimura, M. and Feinberg, A.P. (2004) Microdeletion of LIT1 in
familial Beckwith–Wiedemann syndrome. Am. J. Hum. Genet., 75,
844–849.
15. Prawitt, D., Enklaar, T., Gartner-Rupprecht, B., Spangenberg, C., Oswald,
M., Lausch, E., Schmidtke, P., Reutzel, D., Fees, S., Lucito, R. et al.
(2005) Microdeletion of target sites for insulator protein CTCF in a
chromosome 11p15 imprinting center in Beckwith–Wiedemann
syndrome and Wilms’ tumour. Proc. Natl Acad. Sci. USA, 102,
4085–4090.
16. Cerrato, F., Sparago, A., Farina, L., Ferrero, G.B., Cirillo Silengo, M. and
Riccio, A. (2005) Reply to Microdeletions in the human H19 DMR result
in loss of IGF2 imprinting and Beckwith–Wiedemann. Nat. Genet., 37,
786–787.
17. Sparago, A., Russo, S., Cerrato, F., Ferraiuolo, S., Castorina, P., Selicorni,
A., Schwienbacher, C., Negrini, M., Ferrero, G.B., Silengo, M.C. et al.
(2007) Mechanisms causing imprinting defects in familial Beckwith–
Wiedemann syndrome with Wilms’ tumour. Hum. Mol. Genet., 16,
254–264.
18. Cooper, W.N., Luharia, A., Evans, G.A., Raza, H., Haire, A.C., Grundy,
R., Bowdin, S.C., Riccio, A., Sebastio, G., Bliek, J. et al. (2005)
Molecular subtypes and phenotypic expression of Beckwith–Wiedemann
syndrome. Eur. J. Hum. Genet., 13, 1025–1032.
19. DeBaun, M.R., Niemitz, E.L., McNeil, D.E., Brandenburg, S.A., Lee,
M.P. and Feinberg, A.P. (2002) Epigenetic alterations of H19 and LIT1
distinguish patients with Beckwith–Wiedemann syndrome with cancer
and birth defects. Am. J. Hum. Genet., 70, 604–611.
20. Weksberg, R., Nishikawa, J., Caluseriu, O., Fei, Y.L., Shuman, C., Wei,
C., Steele, L., Cameron, J., Smith, A., Ambus, I. et al. (2001) Tumor
development in the Beckwith–Wiedemann syndrome is associated with a
variety of constitutional molecular 11p15 alterations including imprinting
defects of KCNQ1OT1. Hum. Mol. Genet., 10, 2989–3000.
21. Hao, Y., Crenshaw, T., Moulton, T., Newcomb, E. and Tycko, B. (1993)
Tumour-suppressor activity of H19 RNA. Nature, 365, 764–767.
22. Hark, A.T., Schoenherr, C.J., Katz, D.J., Ingram, R.S., Levorse, J.M. and
Tilghman, S.M. (2000) CTCF mediates methylation-sensitive
enhancer-blocking activity at the H19/Igf2 locus. Nature, 405, 486–489.
23. Bell, A.C. and Felsenfeld, G. (2000) Methylation of a CTCF-dependent
boundary controls imprinted expression of the Igf2 gene. Nature, 405,
482–485.
24. Kurukuti, S., Tiwari, V.K., Tavoosidana, G., Pugacheva, E., Murrell, A.,
Zhao, Z., Lobanenkov, V., Reik, W. and Ohlsson, R. (2006) CTCF
binding at the H19 imprinting control region mediates maternally
inherited higher-order chromatin conformation to restrict enhancer access
to Igf2. Proc. Natl Acad. Sci. USA, 103, 10684–10689.
25. Ling, J.Q., Li, T., Hu, J.F., Vu, T.H., Chen, H.L., Qiu, X.W., Cherry, A.M.
and Hoffman, A.R. (2006) CTCF mediates interchromosomal
colocalization between Igf2/H19 and Wsb1/Nf1. Science, 312, 269–272.
26. Murrell, A., Heeson, S. and Reik, W. (2004) Interaction between
differentially methylated regions partitions the imprinted genes Igf2 and
H19 into parent-specific chromatin loops. Nat. Genet., 36, 889–893.
27. Joyce, J.A., Lam, W.K., Catchpoole, D.J., Jenks, P., Reik, W., Maher,
E.R. and Schofield, P.N. (1997) Imprinting of IGF2 and H19: lack of
reciprocity in sporadic Beckwith–Wiedemann syndrome. Hum. Mol.
Genet., 6, 1543–1548.
28. Feinberg, A.P., Cui, H. and Ohlsson, R. (2002) DNA methylation and
genomic imprinting: insights from cancer into epigenetic mechanisms.
Semin. Cancer Biol., 12, 389–398.
29. Catchpoole, D., Smallwood, A.V., Joyce, J.A., Murrell, A., Lam, W.,
Tang, T., Munroe, D., Reik, W., Schofield, P.N. and Maher, E.R. (2000)
Mutation analysis of H19 and NAP1L4 (hNAP2) candidate genes and
IGF2 DMR2 in Beckwith–Wiedemann syndrome. J. Med. Genet., 37,
212–215.
30. Tokino, T., Urano, T., Furuhata, T., Matsushima, M., Miyatsu, T., Sasaki,
S. and Nakamura, Y. (1996) Characterization of the human p57KIP2
gene: alternative splicing, insertion/deletion polymorphisms in VNTR
sequences in the coding region, and mutational analysis. Hum. Genet., 97,
625–631.
31. Reik, W., Brown, K.W., Schneid, H., Le Bouc, Y., Bickmore, W. and
Maher, E.R. (1995) Imprinting mutations in the Beckwith–Wiedemann
syndrome suggested by altered imprinting pattern in the IGF2–H19
domain. Hum. Mol. Genet., 4, 2379–2385.
32. Schoenherr, C.J., Levorse, J.M. and Tilghman, S.M. (2002) CTCF
maintains differential methylation at the Igf2/H19 locus. Nat. Genet, 33,
66–69.
33. Pant, V., Kurukuti, S., Pugacheva, E., Shamsuddin, S., Mariano, P.,
Renkawitz, R., Klenova, E., Lobanenkov, V. and Ohlsson, R. (2004)
Mutation of a single CTCF target site within the H19 imprinting control
region leads to loss of Igf2 imprinting and complex patterns of de novo
methylation upon maternal inheritance. Mol. Cell. Biol., 24, 3497–3504.
34. Szabo, P.E., Tang, S.H., Silva, F.J., Tsark, W.M. and Mann, J.R. (2004)
Role of CTCF binding sites in the Igf2/H19 imprinting control region.
Mol. Cell. Biol., 24, 4791–4800.
35. Engel, N., Thorvaldsen, J.L. and Bartolomei, M.S. (2006) CTCF binding
sites promote transcription initiation and prevent DNA methylation on the
maternal allele at the imprinted H19/Igf2 locus. Hum. Mol. Genet., 15,
2945–2954.
36. Buiting, K., Gross, S., Lich, C., Gillessen-Kaesbach, G., el-Maarri, O. and
Horsthemke, B. (2003) Epimutations in Prader–Willi and Angelman
syndromes: a molecular study of 136 patients with an imprinting defect.
Am. J. Hum. Genet., 72, 571–577.
37. Fedoriw, A.M., Stein, P., Svoboda, P., Schultz, R.M. and Bartolomei,
M.S. (2004) Transgenic RNAi reveals essential function for CTCF in H19
gene imprinting. Science, 303, 238–240.
38. Jaenisch, R. and Bird, A. (2003) Epigenetic regulation of gene expression:
how the genome integrates intrinsic and environmental signals. Nat.
Genet., 33 (suppl.), 245–254.
39. Cui, H., Niemitz, E.L., Ravenel, J.D., Onyango, P., Brandenburg, S.A.,
Lobanenkov, V.V. and Feinberg, A.P. (2001) Loss of imprinting of
insulin-like growth factor-II in Wilms’ tumour commonly involves altered
methylation but not mutations of CTCF or its binding site. Cancer Res.,
61, 4947–4950.
40. Lew, J.M., Fei, Y.L., Aleck, K., Blencowe, B.J., Weksberg, R. and
Sadowski, P.D. (2004) CDKN1C mutation in Wiedemann–Beckwith
syndrome patients reduces RNA splicing efficiency and identifies a
splicing enhancer. Am. J. Med. Genet. A, 127, 268–276.
Human Molecular Genetics, 2008, Vol. 17, No. 10 1435
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/17/10/1427/594264 by U
niversità degli Studi di M
ilano - Scienze politiche user on 07 April 2020
